Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Publication Title
The New England journal of medicine
Document Type
Article
Publication Date
5-24-2024
Keywords
washington; spokane
Abstract
BACKGROUND: Patients with type 2 diabetes and chronic kidney disease are at high risk for kidney failure, cardiovascular events, and death. Whether treatment with semaglutide would mitigate these risks is unknown.
METHODS: We randomly assigned patients with type 2 diabetes and chronic kidney disease (defined by an estimated glomerular filtration rate [eGFR] of 50 to 75 ml per minute per 1.73 m
RESULTS: Among the 3533 participants who underwent randomization (1767 in the semaglutide group and 1766 in the placebo group), median follow-up was 3.4 years, after early trial cessation was recommended at a prespecified interim analysis. The risk of a primary-outcome event was 24% lower in the semaglutide group than in the placebo group (331 vs. 410 first events; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.88; P = 0.0003). Results were similar for a composite of the kidney-specific components of the primary outcome (hazard ratio, 0.79; 95% CI, 0.66 to 0.94) and for death from cardiovascular causes (hazard ratio, 0.71; 95% CI, 0.56 to 0.89). The results for all confirmatory secondary outcomes favored semaglutide: the mean annual eGFR slope was less steep (indicating a slower decrease) by 1.16 ml per minute per 1.73 m
CONCLUSIONS: Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. (Funded by Novo Nordisk; FLOW ClinicalTrials.gov number, NCT03819153.).
Clinical Institute
Kidney & Diabetes
Specialty
Endocrinology
Specialty
Nephrology
Recommended Citation
Perkovic, Vlado; Tuttle, Katherine R; Rossing, Peter; Mahaffey, Kenneth W; Mann, Johannes F E; Bakris, George; Baeres, Florian M M; Idorn, Thomas; Bosch-Traberg, Heidrun; Lausvig, Nanna Leonora; Pratley, Richard; and and Investigators, FLOW Trial Committees, "Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes." (2024). Articles, Abstracts, and Reports. 8825.
https://digitalcommons.providence.org/publications/8825